FSA
SGMO

Fort Sheridan Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Fort Sheridan Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,723
Closed -$6.89K – 276
2025
Q2 		$6.89K Sell
12,723
-2,418
-16% -$1.44K ﹤0.01% 253
2025
Q1 		$9.93K Sell
15,141
-7,880
-34% -$8.34K ﹤0.01% 248
2024
Q4 		$23.5K Sell
23,021
-110
-0.5% -$201 ﹤0.01% 246
2024
Q3 		$20K Buy
23,131
+1,310
+6% +$960 ﹤0.01% 248
2024
Q2 		$7.82K Sell
21,821
-200
-0.9% -$108 ﹤0.01% 235
2024
Q1 		$14.8K Sell
22,021
-4,357
-17% -$3.16K ﹤0.01% 206
2023
Q4 		$14.3K Sell
26,378
-27,453
-51% -$12.7K ﹤0.01% 200
2023
Q3 		$32.3K Sell
53,831
-12,655
-19% -$13.6K 0.01% 195
2023
Q2 		$86.4K Buy
66,486
+8,688
+15% +$11.9K 0.02% 202
2023
Q1 		$102K Sell
57,798
-1,205
-2% -$3.44K 0.03% 192
2022
Q4 		$185K Sell
59,003
-15,048
-20% -$58.4K 0.06% 175
2022
Q3 		$363K Sell
74,051
-327
-0.4% -$1.68K 0.12% 120
2022
Q2 		$308K Buy
74,378
+400
+0.5% +$1.73K 0.1% 132
2022
Q1 		$430K Sell
73,978
-920
-1% -$5.47K 0.13% 111
2021
Q4 		$562K Sell
74,898
-1,939
-3% -$16.8K 0.16% 101
2021
Q3 		$692K Sell
76,837
-843
-1% -$8.33K 0.23% 78
2021
Q2 		$930K Buy
77,680
+1,735
+2% +$19.6K 0.31% 54
2021
Q1 		$952K Buy
75,945
+4,772
+7% +$64.3K 0.38% 51
2020
Q4 		$1.11M Buy
71,173
+9,540
+15% +$112K 0.54% 31
2020
Q3 		$582K Buy
61,633
+17,478
+40% +$189K 0.34% 47
2020
Q2 		$396K Buy
44,155
+1,880
+4% +$17.4K 0.24% 59
2020
Q1 		$269K Buy
42,275
+14,578
+53% +$108K 0.2% 62
2019
Q4 		$232K Buy
27,697
+4,370
+19% +$40.2K 0.12% 95
2019
Q3 		$211K Buy
+23,327
New +$262K 0.12% 89

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fort Sheridan Advisors's SGMO Position: Q3 2025 in Review

Fort Sheridan Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2025, closing a stake of 12,723 shares — an estimated $6.89K sold.

Fort Sheridan Advisors first reported a position in SGMO in Q3 2019 and held it in 24 quarters. The position peaked at $1.11M in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q3 2025.

  • Fort Sheridan Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2025 after selling out during the quarter.
  • Fort Sheridan Advisors sold 12,723 SANGAMO THERAPEUTICS INC shares in Q3 2025, an estimated $6.89K.
  • Fort Sheridan Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q3 2019 and held it in 24 quarters.
  • Fort Sheridan Advisors's SANGAMO THERAPEUTICS INC position peaked at $1.11M in Q4 2020.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2025.

Based on Fort Sheridan Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.